{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:30:14Z","timestamp":1787009414828,"version":"build-2736575974"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01CA279357-01A1"],"award-info":[{"award-number":["1R01CA279357-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Canadian Research Chair Program"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Central nervous system lymphoma (CNSL), is a rare subtype of non-Hodgkin lymphoma, primarily affecting the brain and spinal cord. Most therapeutic systemic agents have limited penetration of the blood-brain and blood-cerebrospinal fluid (CSF) barrier, with the latter potentially promoting a treatment \u201csanctuary\u201d for cancer cells. Evaluation of occult disease, particularly in the CSF, is challenging. In limited clinical experience, the addition of multiagent intraventricular chemotherapy (MAIVC), delivered through intracranially implanted CSF reservoirs, to systemic therapy has demonstrated encouraging outcomes, enhancing both progression-free survival and overall survival. However, given the potential morbidity associated with MAIVC, identification of minimally invasive biomarkers for guiding patient selection and management is necessary. Leveraging the longitudinal, large volume of CSF, the objective of this study was to identify CSF-based proteomic biomarkers that can serve as reliable indicators of CSF clearance in response to MAIVC and CNSL treatment outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>One hundred fifteen CSF samples from 59 CNSL patients receiving MAIVC were profiled using a high-throughput protocol coupled with mass-spectrometry that only requires 30 \u03bcL of CSF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>More than 2000 unique proteins were detected using shotgun proteomics. Cerebrospinal fluid proteomics revealed key proteins (SGCE, LCP1, AGRN, OLFML3, and HRSP12) distinguishing early from never responders to MAIVC, with area under the receiver operating characteristic (AUROC) 0.86 (95% CI: 0.696-1). By integrating tumor volume from brain MRI scans with proteomic data, we identified potential intraventricular tumor burden markers for CNSL management, in particular LCP1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The study identified CSF-based proteomic biomarkers, particularly LCP1, that can classify MAIVC response and indicate tumor burden in CNSL patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/noajnl\/vdaf046","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T01:29:41Z","timestamp":1740446981000},"source":"Crossref","is-referenced-by-count":5,"title":["Cerebrospinal fluid protein biomarkers are associated with response to multiagent intraventricular chemotherapy in patients with CNS lymphoma"],"prefix":"10.1093","volume":"7","author":[{"given":"Aastha","family":"Aastha","sequence":"first","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network , Toronto, Ontario ,","place":["Canada"]},{"name":"Department of Medical Biophysics, University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Wilding","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Penn State Milton S. Hershey Medical Center , Hershey, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7525-0384","authenticated-orcid":false,"given":"Nicholas","family":"Mikolajewicz","sequence":"additional","affiliation":[{"name":"Division of Neurosurgery, Department of Surgery, University of Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Peter Gilgan Centre for Research and Learning, Hospital for Sick Children , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahbaz","family":"Khan","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Ignatchenko","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo Jose Monteiro","family":"De Macedo Filho","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Penn State Milton S. Hershey Medical Center , Hershey, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debarati","family":"Bhanja","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Penn State Milton S. Hershey Medical Center , Hershey, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Remite-Berthet","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Penn State Milton S. Hershey Medical Center , Hershey, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Heebner","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Penn State Milton S. Hershey Medical Center , Hershey, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4877-5094","authenticated-orcid":false,"given":"Michael","family":"Glantz","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery and Oncology, Penn State Milton S. Hershey Medical Center , Hershey, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7442-7539","authenticated-orcid":false,"given":"Alireza","family":"Mansouri","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Penn State Milton S. Hershey Medical Center , Hershey, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3525-5540","authenticated-orcid":false,"given":"Thomas","family":"Kislinger","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network , Toronto, Ontario ,","place":["Canada"]},{"name":"Department of Medical Biophysics, University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"issue":"6","key":"2025050308211633400_CIT0001","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol (Berl)."},{"issue":"19","key":"2025050308211633400_CIT0002","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood."},{"issue":"4","key":"2025050308211633400_CIT0003","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/bjh.13867","article-title":"Treatment of diffuse large B-cell lymphoma with secondary central nervous system involvement: encouraging efficacy using CNS-penetrating R-IDARAM chemotherapy","volume":"172","author":"Maciocia","year":"2016","journal-title":"Br J Haematol."},{"issue":"10","key":"2025050308211633400_CIT0004","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1093\/annonc\/mdx515","article-title":"Secondary CNS lymphoma: the poisoned needle in the haystack","volume":"28","author":"Ferreri","year":"2017","journal-title":"Ann Oncol"},{"issue":"14","key":"2025050308211633400_CIT0005","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2147\/NDT.S157959","article-title":"Secondary central nervous system lymphoma: spectrum of morphological MRI appearances","volume":"14","author":"Malikova","year":"2018","journal-title":"Neuropsychiatr Dis Treat."},{"issue":"Supplement_5","key":"2025050308211633400_CIT0006","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2015\u20132019","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro-Oncology."},{"issue":"11","key":"2025050308211633400_CIT0007","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1007\/s00277-021-04650-5","article-title":"The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis","volume":"100","author":"Wullenkord","year":"2021","journal-title":"Ann Hematol."},{"issue":"3","key":"2025050308211633400_CIT0008","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/bjh.15661","article-title":"Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma","volume":"184","author":"Fox","year":"2019","journal-title":"Br J Haematol."},{"issue":"1","key":"2025050308211633400_CIT0009","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1186\/s12885-023-11268-5","article-title":"First-line induction chemotherapy with high-dose methotrexate versus teniposide in patients with newly diagnosed primary central nervous system lymphoma: a retrospective, multicenter cohort study","volume":"23","author":"Zhong","year":"2023","journal-title":"BMC Cancer"},{"issue":"3","key":"2025050308211633400_CIT0010","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/bjh.12938","article-title":"Progress in central nervous system lymphomas","volume":"166","author":"Wang","year":"2014","journal-title":"Br J Haematol."},{"issue":"1","key":"2025050308211633400_CIT0011","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2002.20.1.231","article-title":"Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD\/BVAM regimen followed by two different radiotherapy treatments","volume":"20","author":"Bessell","year":"2002","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025050308211633400_CIT0012","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1001\/jamaneurol.2013.606","article-title":"A Systematic Approach to the Diagnosis of Suspected Central Nervous System Lymphoma","volume":"70","author":"Scott","year":"2013","journal-title":"JAMA Neurol"},{"issue":"9","key":"2025050308211633400_CIT0013","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1007\/s004150050459","article-title":"The diagnostic accuracy of magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis","volume":"246","author":"Straathof","year":"1999","journal-title":"J Neurol."},{"issue":"22","key":"2025050308211633400_CIT0014","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1002\/cncr.30965","article-title":"Diagnosis and management of primary central nervous system lymphoma","volume":"123","author":"Han","year":"2017","journal-title":"Cancer."},{"issue":"6","key":"2025050308211633400_CIT0015","first-page":"415","article-title":"Diagnosis of primary central nervous system lymphoma: a systematic review of the utility of CSF screening and the role of early brain biopsy","volume":"6","author":"Morell","year":"2019","journal-title":"Neurooncol. Pract.."},{"issue":"3","key":"2025050308211633400_CIT0016","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","article-title":"Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol"},{"issue":"11","key":"2025050308211633400_CIT0017","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/S2352-3026(17)30174-6","article-title":"Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial","volume":"4","author":"Ferreri","year":"2017","journal-title":"Lancet Haematol"},{"issue":"10","key":"2025050308211633400_CIT0018","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1200\/JCO.18.00306","article-title":"Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study","volume":"37","author":"Houillier","year":"2019","journal-title":"J Clin Oncol."},{"issue":"24","key":"2025050308211633400_CIT0019","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1200\/JCO.2003.04.056","article-title":"Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy","volume":"21","author":"Pels","year":"2003","journal-title":"J Clin Oncol"},{"issue":"11","key":"2025050308211633400_CIT0020","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1200\/JCO.2006.09.7311","article-title":"Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma","volume":"25","author":"Rubenstein","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025050308211633400_CIT0021","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1023\/A:1006210703827","article-title":"Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients","volume":"43","author":"Guha-Thakurta","year":"1999","journal-title":"J Neurooncol."},{"issue":"2","key":"2025050308211633400_CIT0022","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/ana.21824","article-title":"Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma","volume":"67","author":"Juergens","year":"2010","journal-title":"Ann Neurol."},{"issue":"23","key":"2025050308211633400_CIT0023","doi-asserted-by":"crossref","first-page":"e3138","DOI":"10.1212\/WNL.0000000000010949","article-title":"Twenty-year follow-up of a pilot\/phase II trial on the Bonn protocol for primary CNS lymphoma","volume":"95","author":"Seidel","year":"2020","journal-title":"Neurology."},{"issue":"3","key":"2025050308211633400_CIT0024","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00277-008-0645-y","article-title":"Intrathecal chemotherapy for hematologic malignancies: drugs and toxicities","volume":"88","author":"Kwong","year":"2009","journal-title":"Ann Hematol."},{"issue":"6","key":"2025050308211633400_CIT0025","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1016\/j.prro.2017.05.002","article-title":"Craniospinal irradiation prior to stem cell transplant for hematologic malignancies with CNS involvement: effectiveness and toxicity after photon or proton treatment","volume":"7","author":"Gunther","year":"2017","journal-title":"Pract Radiat Oncol"},{"issue":"1","key":"2025050308211633400_CIT0026","first-page":"vdac161","article-title":"Leveraging the CSF proteome toward minimally-invasive diagnostics surveillance of brain malignancies","volume":"4","author":"Mikolajewicz","year":"2022","journal-title":"Neurooncol. Adv."},{"issue":"2","key":"2025050308211633400_CIT0027","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/jnc.15350","article-title":"Diagnostic biomarkers from proteomic characterization of cerebrospinal fluid in patients with brain malignancies","volume":"158","author":"Schmid","year":"2021","journal-title":"J Neurochem."},{"issue":"10","key":"2025050308211633400_CIT0028","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1074\/mcp.O115.049650","article-title":"MStern blotting-high throughput Polyvinylidene Fluoride (PVDF) membrane-based proteomic sample preparation for 96-well plates","volume":"14","author":"Berger","year":"2015","journal-title":"Mol Cell Proteom"},{"issue":"12","key":"2025050308211633400_CIT0029","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/nbt.1511","article-title":"MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification","volume":"26","author":"Cox","year":"2008","journal-title":"Nat Biotechnol."},{"issue":"3","key":"2025050308211633400_CIT0030","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.stem.2016.06.008","article-title":"Ectopic miR-125a expression induces long-term repopulating stem cell capacity in mouse and human hematopoietic progenitors","volume":"19","author":"Wojtowicz","year":"2016","journal-title":"Cell Stem Cell"},{"issue":"5","key":"2025050308211633400_CIT0031","doi-asserted-by":"crossref","first-page":"101624","DOI":"10.1016\/j.esmoop.2023.101624","article-title":"Leptomeningeal metastasis from solid tumours: EANO\u2013ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"8","author":"Le Rhun","year":"2023","journal-title":"ESMO Open"},{"issue":"23","key":"2025050308211633400_CIT0032","doi-asserted-by":"crossref","first-page":"e114665","DOI":"10.15252\/embj.2023114665","article-title":"A region-resolved proteomic map of the human brain enabled by high-throughput proteomics","volume":"42","author":"T\u00fcshaus","year":"2023","journal-title":"EMBO J."},{"issue":"1","key":"2025050308211633400_CIT0033","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1038\/s41467-022-30050-y","article-title":"The genomic and transcriptional landscape of primary central nervous system lymphoma","volume":"13","author":"Radke","year":"2022","journal-title":"Nat Commun."},{"issue":"1","key":"2025050308211633400_CIT0034","doi-asserted-by":"crossref","first-page":"100012","DOI":"10.1016\/j.esmoop.2020.100012","article-title":"Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence","volume":"6","author":"Magnes","year":"2021","journal-title":"ESMO Open"},{"issue":"3","key":"2025050308211633400_CIT0035","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s11060-018-2749-0","article-title":"MicroRNA-30c as a novel diagnostic biomarker for primary and secondary B-cell lymphoma of the CNS","volume":"137","author":"Baraniskin","year":"2018","journal-title":"J Neurooncol."},{"issue":"3","key":"2025050308211633400_CIT0036","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jmoldx.2021.11.005","article-title":"Distinct miRNA expression signatures of primary and secondary central nervous system lymphomas","volume":"24","author":"Sebesty\u00e9n","year":"2022","journal-title":"J Mol Diagn."},{"issue":"4","key":"2025050308211633400_CIT0037","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1182\/blood-2011-02-335125","article-title":"A unique proteomic profile on surface IgM ligation in unmutated chronic lymphocytic leukemia","volume":"118","author":"Perrot","year":"2011","journal-title":"Blood."},{"issue":"1","key":"2025050308211633400_CIT0038","first-page":"935173","article-title":"The actin-bundling protein L-plastin: a critical regulator of immune cell function","volume":"2012","author":"Morley","year":"2012","journal-title":"Int J Cell Biol"},{"issue":"12","key":"2025050308211633400_CIT0039","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1002\/ijc.22589","article-title":"Phosphorylation of ectopically expressed L-plastin enhances invasiveness of human melanoma cells","volume":"120","author":"Klemke","year":"2007","journal-title":"Int J Cancer."},{"issue":"19","key":"2025050308211633400_CIT0040","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1182\/blood-2013-05-504597","article-title":"Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood."},{"issue":"6","key":"2025050308211633400_CIT0041","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1200\/JCO.1986.4.6.859","article-title":"Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma","volume":"4","author":"Jagannath","year":"1986","journal-title":"J Clin Oncol"},{"issue":"19","key":"2025050308211633400_CIT0042","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv."},{"issue":"2","key":"2025050308211633400_CIT0043","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0301-472X(00)00651-2","article-title":"A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients","volume":"29","author":"Ladetto","year":"2001","journal-title":"Exp Hematol."},{"issue":"6","key":"2025050308211633400_CIT0044","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/1097-0142(19800315)45:6<1507::AID-CNCR2820450634>3.0.CO;2-D","article-title":"Prognostic factors in Burkitt\u2019s lymphoma: importance of total tumor burden","volume":"45","author":"Magrath","year":"1980","journal-title":"Cancer."},{"issue":"10","key":"2025050308211633400_CIT0045","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1001\/archderm.135.10.1204","article-title":"Tumor burden index as a prognostic tool for cutaneous T-cell lymphoma: a new concept","volume":"135","author":"Schmid","year":"1999","journal-title":"Arch Dermatol."},{"issue":"12","key":"2025050308211633400_CIT0046","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1111\/1759-7714.13214","article-title":"Comparisons between tumor burden and other prognostic factors that influence survival of patients with non-small cell lung cancer treated with immune checkpoint inhibitors","volume":"10","author":"Sakata","year":"2019","journal-title":"Thorac Cancer"},{"issue":"3","key":"2025050308211633400_CIT0047","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ejca.2014.11.023","article-title":"Tumour size is the only predictive factor of distant recurrence after pathological complete response to neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancers: a sub-study of EORTC 10994\/BIG 1-00 phase III trial","volume":"51","author":"Fei","year":"2015","journal-title":"Eur J Cancer"},{"issue":"11","key":"2025050308211633400_CIT0048","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1200\/JCO.2009.25.3286","article-title":"Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer","volume":"28","author":"Caudle","year":"2010","journal-title":"J Clin Oncol"},{"issue":"20","key":"2025050308211633400_CIT0049","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.1158\/1078-0432.CCR-18-1311","article-title":"Bigger is not always better: tumor size and prognosis in advanced melanoma","volume":"24","author":"Warner","year":"2018","journal-title":"Clin. Cancer Res"}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdaf046\/62154449\/vdaf046.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/7\/1\/vdaf046\/62154449\/vdaf046.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/7\/1\/vdaf046\/62154449\/vdaf046.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T08:21:30Z","timestamp":1746260490000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdaf046\/8040890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdaf046","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2025,1]]},"article-number":"vdaf046"}}